This month-long multicenter, open-label study evaluated the onset and progression of @entity450 associated with bimatoprost 0.03% once daily in 39 @entity1 with @entity1538 or @entity2790 . Current @entity726 medication(s) was either replaced with or augmented by bimatoprost. Previous users of bimatoprost were excluded. Primary outcome measures were mean @entity450 scale scores (ciliary, conjunctival, and episcleral, graded on a seven-point scale) and incidence of @entity450 . Secondary outcome measures were @entity941 staining, @entity1 assessment of ocular redness (take-home diary), and @entity1 and investigator evaluations. @entity1 were asked how troubled they were by their ocular redness. Investigators were asked if they would continue the @entity1 on bimatoprost despite the @entity450 . Overall, the frequency and severity of @entity450 peaked approximately 1 day after the first instillation of bimatoprost and decreased consistently throughout the study, returning to near-baseline levels by day 28. At day 1, 84.6% of @entity1 were hardly troubled or not troubled by their ocular redness; only 15.4% were somewhat or moderately troubled. Investigators indicated that they would continue bimatoprost therapy in 92.3% of the @entity1 . @entity450 did not represent a significant safety concern.

Multicenter, open-label evaluation of @entity450 associated with use of bimatoprost in adults with XXXX or @entity2790 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity1538 :: ('MESH:D005902', 'Disease') :: ['open-angle glaucoma'] @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma'] @entity450 :: ('MESH:D006940', 'Disease') :: ['hyperemia', 'Hyperemia'] @entity2790 :: ('MESH:D009798', 'Disease') :: ['ocular hypertension'] @entity941 :: ('MESH:D019793', 'Chemical') :: ['fluorescein']
@entity1538 :: (MESH:D005902,Disease) :: ['open-angle glaucoma']
